Permit allows LGP to manufacture cannabis extracts for supply to holders of Therapeutic Goods Administration.
Little Green Pharma Ltd (ASX: LGP) is pleased to announce the grant of a new Manufacture Permit over its manufacturing facility by the Office of Drug Control.
Receiving this Manufacture Permit gives us the internal capability to manufacture cannabis extracts at our manufacturing premises and is a significant event for Little Green Pharma.Fleta Solomon, Managing Director of LGP
The Manufacture Permit will allow LGP to manufacture cannabis extracts for supply to holders of Therapeutic Goods Administration GMP manufacturing licences to produce finished medicinal cannabis products. The Company has an exclusive agreement with its TGA GMP-licenced Manufacturing Partner to produce such products. The Permit has been granted until 10 March 2021, which aligns it with the terms of LGP's ODC
Medicinal Cannabis and Manufacture licences.
This Permit will enable LGP to commence in-house extraction once the next crop is harvested, resulting in reduced manufacturing costs and improved manufacturing efficiencies.
Commenting on the grant of the Manufacture Permit, LGP Managing Director Fleta Solomon said:
"We are now only waiting for our expanded ODC Medicinal Cannabis Cultivation and Production Permit which, once granted, will allow us to begin first planting at our expanded cultivation facility and to significantly expand our production operations. This increased production capacity will give Little Green Pharma the ability to meet both Australian and offshore demand for medicinal cannabis products.
I look forward to updating the market once our expanded ODC Medicinal Cannabis Cultivation and Production Permit is granted."
Disclaimer: Past performance is not an indicator of future performance.
& Keep Up to Date
Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!